drugset
drugset / Trial / NCT06586866

JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases

NCT06586866 ↗

Phase 2 Not yet recruiting 25 enrolled JenKem Technology Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study was designed to evaluate the safety, efficacy and pharmacokinetics of JK-1201I in triple negative breast cancer patients with brain metastases.

Timeline

Start
2024-09-26
Primary completion
2026-05-26
Completion
2026-10-26

Drugs

EvaluationDrugModalityDoseRoute
Subject JK-1201I Unknown 125 mg/m2 Intravenous

Indications

metastatic malignant neoplasm in the brain triple-negative breast carcinoma